Your browser is no longer supported. Please, upgrade your browser.
ACHN Achillion Pharmaceuticals, Inc. daily Stock Chart
Achillion Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-0.62 Insider Own0.11% Shs Outstand140.66M Perf Week-3.38%
Market Cap562.64M Forward P/E- EPS next Y-0.62 Insider Trans-99.15% Shs Float137.70M Perf Month32.89%
Income-85.20M PEG- EPS next Q-0.14 Inst Own86.80% Short Float6.23% Perf Quarter41.84%
Sales- P/S- EPS this Y-37.60% Inst Trans-8.83% Short Ratio3.79 Perf Half Y3.63%
Book/sh2.35 P/B1.70 EPS next Y-10.70% ROA-23.20% Target Price5.36 Perf Year4.17%
Cash/sh2.13 P/C1.87 EPS next 5Y17.58% ROE-24.10% 52W Range2.58 - 5.66 Perf YTD38.89%
Dividend- P/FCF- EPS past 5Y0.50% ROI- 52W High-29.33% Beta1.00
Dividend %- Quick Ratio23.60 Sales past 5Y- Gross Margin- 52W Low55.04% ATR0.20
Employees88 Current Ratio23.60 Sales Q/Q- Oper. Margin- RSI (14)63.80 Volatility4.52% 6.05%
OptionableYes Debt/Eq0.00 EPS Q/Q-419.60% Profit Margin- Rel Volume1.57 Prev Close3.87
ShortableYes LT Debt/Eq0.00 EarningsFeb 22 BMO Payout- Avg Volume2.26M Price4.00
Recom2.30 SMA209.45% SMA5024.75% SMA2004.03% Volume3,501,859 Change3.36%
Feb-08-18Initiated B. Riley FBR, Inc. Neutral $3.50
Sep-12-17Reiterated Ladenburg Thalmann Buy $9 → $6.50
Aug-10-17Downgrade Robert W. Baird Outperform → Neutral $5
Aug-09-17Reiterated Chardan Capital Markets Neutral $5 → $4
May-18-17Upgrade Leerink Partners Mkt Perform → Outperform
Feb-02-17Initiated Ladenburg Thalmann Buy $10
Nov-04-16Upgrade Chardan Capital Markets Sell → Neutral $5
Sep-23-16Reiterated Chardan Capital Markets Sell $4 → $5
Sep-23-16Initiated Wedbush Outperform $13
Sep-15-16Initiated FBR & Co. Outperform $16
Jul-14-16Initiated Chardan Capital Markets Sell $4
Jul-07-16Upgrade JMP Securities Mkt Perform → Mkt Outperform
Feb-26-16Upgrade Robert W. Baird Neutral → Outperform $10
Feb-25-16Reiterated Maxim Group Buy $11 → $8
Sep-09-15Initiated Jefferies Hold
Aug-13-15Reiterated Maxim Group Buy $19 → $11
May-20-15Reiterated Leerink Partners Outperform $25 → $16
May-20-15Downgrade JMP Securities Mkt Outperform → Mkt Perform
Mar-10-15Reiterated Maxim Group Buy $22 → $19
Mar-04-15Initiated Barclays Underweight $8
Mar-20-18 08:37AM  Are Options Traders Betting on a Big Move in Achillion Pharmaceuticals (ACHN) Stock? Zacks
Mar-14-18 02:58PM  Catalyst Pharmaceuticals Inc (CPRX) and Achillion Pharmaceuticals, Inc. (ACHN) Among Five Cheap Healthcare Stocks To Buy Now Insider Monkey
Mar-13-18 07:35AM  Report: Developing Opportunities within Mimecast, Mazor Robotics, JD, Achillion Pharmaceuticals, Kulicke and Soffa Industries, and Weibo Future Expectations, Projections Moving into 2018 GlobeNewswire
Mar-08-18 06:05AM  Achillion to Present at the Barclays Global Healthcare Conference GlobeNewswire +7.80%
Mar-05-18 07:00AM  Groupon Inc (GRPN), Globalstar, Inc. (GSAT) & More: Five Cheap Stocks to Buy Now Insider Monkey
Mar-01-18 12:16PM  [$$] Big Biotech Buys: Vericel, Achillion, PTC, Dicerna
Feb-28-18 06:05AM  Achillion Raises Awareness for C3 Glomerulopathy With Launch of WeC3G Initiative as Part of Rare Disease Day 2018 GlobeNewswire -5.52%
Feb-27-18 08:44AM  Achillion Pharmaceuticals (ACHN) Soars: Stock Adds 15.4% in Session Zacks
08:30AM  Todays Research Reports on Trending Tickers: Achillion Pharmaceuticals and Novavax ACCESSWIRE
07:40AM  Wired News Bellicum Pharma Shares Update On Clinical Hold of BPX-501 Studies in the US ACCESSWIRE
Feb-26-18 06:14PM  Why Achillion Pharmaceuticals, Inc. Stock Spiked Today Motley Fool +15.40%
08:20AM  Benzinga Pro's 4 Stocks To Watch Today Benzinga
06:05AM  Achillion Announces ACH-4471 Receives Positive Opinion for Orphan Drug Designation in the European Union for the Treatment of C3 Glomerulopathy GlobeNewswire
Feb-23-18 09:19AM  Achillion (ACHN) Q4 Loss Widens, Plans Job Cuts to Save Cost Zacks
Feb-22-18 12:43PM  Was Achillion Pharmaceuticals Incs (NASDAQ:ACHN) Earnings Decline A Part Of Broader Industry Downturn? Simply Wall St.
06:21AM  Achillion reports 4Q loss Associated Press
06:05AM  Achillion Announces Restructuring to Advance Corporate Strategy; Announces 2017 Fourth Quarter and Full Year Financial Results GlobeNewswire
Feb-09-18 06:05AM  Achillion to Present at the Leerink Partners 7th Annual Global Healthcare Conference GlobeNewswire
Dec-28-17 09:45AM  Actinium Posts Positive DMC View on Lomab-B Phase III Trial Zacks
Dec-27-17 11:29AM  Insys' Cannabidiol Gets Fast Track Designation in the U.S. Zacks
08:11AM  Alexion's (ALXN) Soliris Label Expansion Approved in Japan Zacks
Dec-26-17 09:17AM  BioMarin's (BMRN) Pegvaliase Review Period Extended by FDA Zacks
Dec-20-17 12:12PM  CORRECTION - Achillion Pharmaceuticals, Inc. GlobeNewswire
06:05AM  Achillion Initiates Phase I First-In Study of ACH-5228, a Next-Generation Oral Small Molecule Inhibitor of Complement Factor D GlobeNewswire
Dec-18-17 06:30AM  Achillion Announces ACH-4471 Granted Orphan Drug Designation for the Treatment of C3 Glomerulopathy (C3G) and the Initiation of a Phase 1 Extended-Release Bioavailability Study GlobeNewswire
Dec-13-17 03:46PM  Allergan Inks Deal to Buy Texas-Based Repros Therapeutics Zacks
Dec-12-17 05:58PM  Merck's Keytruda Gets FDA Priority Review for Rare Lymphoma Zacks
Dec-06-17 02:10PM  Revance's Neuromodulator Injection Positive in Phase III Zacks
Dec-05-17 08:20AM  Todays Research Reports on Trending Tickers: Achillion Pharmaceuticals and Zynerba Pharmaceuticals ACCESSWIRE
Dec-04-17 09:03AM  Pfizer Wins China & Asia-Pacific Rights to Anti-Fungal Drug Zacks
Dec-01-17 05:51PM  Celldex Begins Phase I Trial on Cancer Candidate CDX-1140 Zacks
Nov-27-17 12:48PM  [$$] J&J Lost $175 Million on Achillion Stock Investment
Nov-23-17 09:12AM  Glaxo (GSK) Files for U.S. Label Expansion of COPD Inhaler Zacks
08:42AM  Puma Inks License Deal to Commercialize Cancer Drug Nerlynx Zacks
Nov-20-17 03:42PM  Agios Posts New Data on Glioma Candidate from Dose Expansion Zacks
Nov-16-17 03:36PM  Here's Why Achillion Pharmaceuticals Is Soaring 19.5% Today Motley Fool +17.49%
10:35AM  Achillion Pharmaceuticals Gears Up for Secondary Offering 24/7 Wall St.
08:20AM  Todays Research Reports on Trending Tickers: Achillion Pharmaceuticals and Aurinia Pharmaceuticals ACCESSWIRE
Nov-15-17 10:05PM  Achillion Announces Pricing of Secondary Offering Of Common Stock GlobeNewswire -17.89%
01:37PM  Why Achillion Pharmaceuticals Stock Is Falling Today Motley Fool
01:30PM  Achillion (ACHN) Shares Down as J&J Announces Stake Sale Zacks
12:28PM  Achillion Heel: Stock Plunges as J&J Exits
08:16AM  Biotech Stock Roundup: Dynavax Vaccine Gets FDA Nod, Loxo Inks Deal with Bayer Zacks
06:36AM  Cardinal Health (CAH) to Divest Assets to Shanghai Pharma Zacks
Nov-14-17 04:53PM  Theravance (TBPH) Submits NDA for COPD Candidate Revefenacin Zacks
04:34PM  Achillion shares drop as J&J to sell large stake MarketWatch
04:03PM  Achillion Announces Proposed Secondary Offering of Common Stock GlobeNewswire
04:01PM  Achillion Reports Preliminary Proof-of-Concept With ACH-4471 for the Treatment of C3G GlobeNewswire
09:48AM  Glaxo's Subcutaneous Formulation of Benlysta Approved in EU Zacks
Nov-06-17 06:05AM  Achillion Announces ACH-4471 Granted Orphan Drug Designation by the FDA and Positive Opinion for Orphan Drug Designation in the European Union for the Treatment of Paroxysmal Nocturnal Hemoglobinuria GlobeNewswire
Nov-03-17 01:08PM  Achillion (ACHN) Q3 Loss Narrows, Pipeline Expansion in Focus Zacks
Nov-01-17 06:02PM  Achillion reports 3Q loss Associated Press
04:05PM  Achillion Reports Third Quarter 2017 Financial Results and Provides Update on Clinical Programs GlobeNewswire
12:25PM  Has Achillion Pharmaceuticals Inc (ACHN) Got Enough Cash To Cover Its Short-Term Obligations? Simply Wall St.
Oct-24-17 06:05AM  USPTO Grants Composition of Matter Patent to Achillion for ACH-4471, First-in-Class Small Molecule Complement Alternative Pathway Factor D Inhibitor GlobeNewswire
Oct-23-17 07:00AM  Achillion Announces Presentation of Data From OMEGA-1 Phase 2b Trial With Odalasvir, AL-335, and Simeprevir (JNJ-4178) at the 2017 Liver Meeting GlobeNewswire
Oct-18-17 10:08AM  Achillion Pharmaceuticals, Inc. Value Analysis (NASDAQ:ACHN) : October 18, 2017 Capital Cube
Oct-17-17 08:15AM  Achillion Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : ACHN-US : October 17, 2017 Capital Cube
Sep-20-17 06:05AM  Achillion to Present at the 2017 Leerink Partners Rare Disease Roundtable Series GlobeNewswire +5.96%
Sep-15-17 06:52AM  Pharma Stock Roundup: Achillion Slumps on End of HCV Deal, Teva Gets a New CEO Zacks
Sep-12-17 11:39AM  Achillion's HCV Partnership with J&J Terminated, Stock Falls Zacks
11:30AM  Achillion Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : ACHN-US : September 12, 2017 Capital Cube
08:10AM  Today's Research Reports on Stocks to Watch: Achillion Pharmaceuticals and Idera Pharmaceuticals ACCESSWIRE
Sep-11-17 04:30PM  Why Achillion Pharmaceuticals Crashed 22.2% Today Motley Fool -22.10%
09:46AM  Achillion Shares Are Plunging on Termination of Hepatitis C Pact
08:50AM  Achillion Pharma Slides After Hep C Deal Is Terminated 24/7 Wall St.
08:34AM  Achillion Pharmaceuticals falls 25% after hepatitis C deal with J&J unit ends CNBC
03:02AM  Achillion Announces Strengthening of Management Team GlobeNewswire
03:01AM  Achillion Announces Termination of Worldwide Collaboration for Hepatitis C With Janssen GlobeNewswire
Aug-16-17 04:30PM  Edited Transcript of ACHN earnings conference call or presentation 8-Aug-17 8:05pm GMT Thomson Reuters StreetEvents
Aug-11-17 07:20AM  Corporate News Blog - Achillion Announces Proof-of-Concept with a First-in-Class, Oral Factor D Inhibitor ACCESSWIRE +5.98%
Aug-10-17 11:06AM  Achillion Pharmaceuticals Stock Falls, Baird Downgrades Over Lack of Confidence -7.90%
08:21AM  Achillion Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : ACHN-US : August 10, 2017 Capital Cube
08:20AM  Today's Research Reports on Stocks to Watch: Achillion Pharmaceuticals and ACADIA Pharmaceuticals ACCESSWIRE
Aug-09-17 01:06PM  2 Reasons Behind Achillion Pharmaceuticals, Inc.'s 11% Tumble in July Motley Fool +19.95%
12:57PM  Why Achillion Pharmaceuticals Is Shooting 25% Higher Today Motley Fool
11:59AM  These Two Biotech Stocks Are Going Berserk on Wednesday
11:15AM  3 Biotech Stocks Under the Microscope on Wednesday 8/9/17 ACCESSWIRE
10:51AM  Achillion (ACHN) Q2 Loss In Line, Gains on Pipeline Update Zacks
Aug-08-17 11:54PM  Achillion reports 2Q loss Associated Press
05:38PM  Achillion shares rally as blood disorder treatment shows promise MarketWatch
04:01PM  Achillion Reports Second Quarter 2017 Financial Results and Proof-of-Concept With a First-in-Class, Oral Factor D Inhibitor GlobeNewswire
09:00AM  Investor Network: Achillion Pharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE
Aug-01-17 05:39PM  Achillion Pharmaceuticals, Inc. Value Analysis (NASDAQ:ACHN) : August 1, 2017 Capital Cube
04:05PM  Achillion to Host Second Quarter 2017 Results Conference Call on August 8, 2017 GlobeNewswire
Jul-20-17 08:38AM  Is the Options Market Predicting a Spike in Achillion Pharmaceuticals (ACHN) Stock? Zacks
Jul-19-17 09:09AM  Achillion Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : ACHN-US : July 19, 2017 Capital Cube
Jul-10-17 04:05PM  Achillion Pharmaceutials Announces Key Promotion and Discovery Organization Change GlobeNewswire
Jun-22-17 08:00AM  Achillion Pharmaceuticals Financials, Price Targets and Pipeline Review Accesswire
Jun-15-17 04:05PM  Achillion to Present at the 2017 JMP Securities Life Sciences Conference GlobeNewswire
Jun-09-17 04:17AM  Achillion (ACHN) Up 31.1% Since Earnings Report: Can It Continue? Zacks
Jun-05-17 04:51PM  Achillion to Present at the Jefferies 2017 Global Healthcare Conference GlobeNewswire
08:00AM  Today's Research Reports on Stocks to Watch: Achillion Pharmaceuticals and TG Therapeutics Accesswire
May-19-17 08:00AM  Today's Research Reports on Biotech Stocks to Watch: Achillion Pharmaceuticals and CytRx Accesswire
May-18-17 02:26PM  Why Achillion Pharmaceuticals Stock Is Jumping 15% Today Motley Fool +16.67%
12:10PM  Achillion: It Can't Get Any WorseOr Can It?
May-11-17 06:04PM  Achillion Pharmaceuticals, Inc. Value Analysis (NASDAQ:ACHN) : May 11, 2017 Capital Cube
May-10-17 08:15AM  Achillion Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : ACHN-US : May 10, 2017 Capital Cube
May-08-17 02:01PM  Achillion (ACHN) Reports Wider-than-Expected Loss in Q1 Zacks
May-04-17 06:24AM  Achillion reports 1Q loss Associated Press
Achillion Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes small molecule drug therapies for immune system disorders in the United States. Its lead drug candidate includes ACH-4471, an inhibitor of factor D that is Phase II clinical trials for patients with paroxysmal nocturnal hemoglobinuria and C3 glomerulopathy. The company is also developing ACH-5228, a factor D inhibitor that is in Phase I clinical trial; ACH-5548, a factor D inhibitor; and other factor D inhibitors. It has license agreements with GCA Therapeutics, Ltd and Ora, Inc., as well as a collaboration arrangement with Janssen Pharmaceuticals Inc. to develop and commercialize drug candidates for the treatment of chronic hepatitis C virus. The company was founded in 1998 and is headquartered in New Haven, Connecticut.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
JOHNSON & JOHNSON10% OwnerNov 20Sale2.7518,367,34650,510,2020Nov 22 11:44 AM
VITULLO NICOLEDirectorAug 10Option Exercise3.112,811,2458,750,0005,108,336Aug 14 04:47 PM